Global Blood Therapeutics, Inc. (NASDAQ:GBT) Files An 8-K Other EventsItem 8.01. Other Events.
On December 9, 2017, Global Blood Therapeutics, Inc. (“GBT”) issued a press release titled “GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease.” On December 11, 2017, GBT issued a press release titled “GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease Program.” Copies of the press releases are filed as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
On December 11, 2017, GBT hosted an investor webcast, during which it presented an analysis of patient reported outcome (PRO) data from its Phase 3 HOPE study pretreatment screening. These data included over 2,500 completions of the PRO which were taken as part of the initial screening required to be completed by patients before entering the study. During this screening period, patients completed the daily nine PRO questions and three anchor questions. These screening data were used to evaluate sensitivity to change and estimate on a preliminary basis what can constitute meaningful change scores using the PRO.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Global Blood Therapeutics, Inc. ExhibitEX-99.1 2 exh_991.htm EXHIBIT 99.1 EdgarFilingEXHIBIT 99.1GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD)Data to be Highlighted in ASH Press Briefing and Company to Host Investor Webcast on Monday,…To view the full exhibit click here
About Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company’s segment is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. It is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is evaluating GBT440 in SCD subjects in an ongoing Phase I/II clinical trial. SCD is a genetic disease marked by red blood cell (RBC) destruction and occluded blood flow and hypoxia, leading to anemia, stroke, multi-organ failure, severe pain crises, and shortened patient life span. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. It is also engaged in other research and development activities targeted towards hereditary angioedema (HAE).
